Influencing factors of radioiodine therapy in hyperthyroidism in adults

Influencing factors of radioiodine therapy in hyperthyroidism in adults 1 first-author 1 1 2 1 3 corresp Corresponding author. E-mail: gzshsums@public.guangzhou.gd.cn Corresponding author. E-mail: gzshsums@public.guangzhou.gd.cn gzshsums@public.guangzhou.gd.cn Department of Nuclear Medicine, No.3 Hospital Affiliated to Sun Yat-sen University, Guangzhou 510630, China; Department of Nuclear Medicine, No.3 Hospital Affiliated to Sun Yat-sen University, Guangzhou 510630, China; Department of Infection Disease, No.3 Hospital Affiliated to Sun Yat-sen University, Guangzhou 510630, China; Department of Infection Disease, No.3 Hospital Affiliated to Sun Yat-sen University, Guangzhou 510630, China; Department of Radiology, No.3 Hospital Affiliated to Sun Yat-sen University, Guangzhou 510630, China Department of Radiology, No.3 Hospital Affiliated to Sun Yat-sen University, Guangzhou 510630, China The study was to evaluate factors affecting outcome of 131 I therapy in hyperthyroidism for optimizing the method. Data from 213 patients who received 131 I treatment from July 2003 to July 2005 in our department were retrospectively analyzed. Factors possibly contributing to the outcome of the 131 I therapy were analyzed, including gender, age, history of antithyroid drug, thyroid volume, duration of disease and radioactive iodine uptake rate. Multivariate analysis was done. The rates of euthyroidism and hypothyroidism were 69% and 8.5%, respectively, after one time 131 I therapy. Multivariate analysis of the patients showed no statistically significant factors affecting the outcome of 131 I therapy. The study showed that 131 I dose can be directly calculated, and this simplifies the dose-determined method and individualizes the therapy. Iodine-131 Hyperthyroidism Factors Adult References Franklyn J A , Daykin J , Holder R , et al . QJM , 1995 , 88 ( 3 ): 175 - 180 . QJM Safe A F , Maxwell R T . Br J Clin Pract . 1990 , 44 ( 10 ): 393 - 395 . Br J Clin Pract Ratcliffe G E , Fogelman I , Maisey M N . Br J Radiol , 1986 , 59 ( 707 ): 1105 - 1107 . Br J Radiol Watson A B , Brownlie B E W , Frampton C M , et al . Clin Endocrinol (Oxf) , 1988 , 28 ( 5 ): 487 - 496 . Clin Endocrinol (Oxf) Nordyke R A , Gilbert F I . J Nucl Med , 1991 , 32 ( 3 ): 411 - 416 . J Nucl Med De Bruin T W A , Croon C D L , De Klerk J M H , et al . J Intern Med , 1994 , 236 ( 5 ): 507 - 513 . J Intern Med Torring O , Tallstedt L , Wallin G , et al . J Clin Endocrinol Metab , 1996 , 81 ( 8 ): 2986 - 2993 . J Clin Endocrinol Metab Rosenthall L . J Can Assoc Radiol , 1972 , 23 ( 3 ): 171 - 175 . J Can Assoc Radiol Sridama V , McCormick M , Kaplan E L , et al . N Engl J Med , 1984 , 311 ( 7 ): 426 - 432 . N Engl J Med Willemsen U F , Knesewitsch P , Kreisig T , et al . Eur J Nucl Med , 1993 , 20 ( 11 ): 1051 - 1055 . Eur J Nucl Med Kung A W C , Choi P , Lam K S L , et al . Clin Radiol , 1990 , 42 ( 1 ): 52 - 54 . Clin Radiol Peters H , Fischer C , Bogner U , et al . Thyroid , 1997 , 7 ( 2 ): 247 - 251 . Thyroid Sabri O , Zimny M , Schulz G , et al . J Clin Endocrinol Metab , 1999 , 84 ( 4 ): 1229 - 1233 . J Clin Endocrinol Metab Braga M , Walpert N , Burch H B , et al . Thyroid , 2002 , 12 ( 2 ): 135 - 139 . Thyroid Sabri O , Zimny M , Schreckenberger M , et al . Nuklearmedizin , 2001 , 40 ( 1 ): 1 - 6 . Nuklearmedizin Ruchala M , Sowinski J , Dolata M , et al . Nucl Med Rev Cent East Eur , 2005 , 8 ( 1 ): 28 - 32 . Nucl Med Rev Cent East Eur Listewnik M H . Ann Acad Med Stetin , 2000 , 46 : 109 - 121 . Ann Acad Med Stetin Veliz J , Pineda G , Arancibia P , et al . Rev Med Chil , 2000 , 128 ( 6 ): 609 - 612 . Rev Med Chil 10.1016/S1001-8042(07)60064-5 R817.5,R581.1 2007-06-30 2007-10-20 2021-01-19 2007 Nuclear Science and Techniques 05 18